SQZB.US SQZ Biotechnologies Company

Healthcare Biotechnology USA Stocks
0.0240 USD
Close of Nov 18, 2026
0.0228 0.0300
Market cap
USD 708K
P/E
-
P/B
0.44x
ROE
-
Dividend yield
-
Fundamental score
-

Is SQZB.US undervalued?

Graham number

The Graham number of SQZ Biotechnologies Company cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

SQZ Biotechnologies Company fundamental analysis

No fundamental analysis for SQZ Biotechnologies Company yet.

SQZ Biotechnologies Company stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About SQZ Biotechnologies Company

SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, infectious diseases, and other serious conditions in Massachusetts. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck,…

Full company profile